Verici Dx shares jump 23% as transplant test rollout gathers pace

Verici Dx shares jumped 23% after the company reported significant commercial progress for its Tutivia kidney transplant test, onboarding nine new U.S. transplant centers in Q3, bringing the total to 30 and representing approximately 16% of annual U.S. transplants. Clinician orders for Tutivia rose 19% over the period, with management anticipating accelerated sales volumes in Q4 and reaffirming its trajectory to meet full-year market expectations, signaling robust market penetration and potential revenue growth.

Analysis

Verici Dx shares jump 23% as transplant test rollout gathers pace Last updated: 09:30 06 Oct 2025 BST, First published: 09:20 06 Oct 2025 BST Shares in Verici Dx PLC (AIM:VRCI) surged 23% in early trading on Monday after the diagnostics company reported encouraging progress in the commercial rollout of its Tutivia test for kidney transplant patients and announced changes to its board. The London-listed group said it had onboarded nine new transplant centres in the United States during the third quarter, taking the total to 30. These centres now represent around 16% of annual US transplants. The number of clinicians ordering Tutivia, which detects early signs of organ rejection, rose by 19% over the period. Verici said it expects sales volumes to accelerate in the final quarter of the year as newly signed centres begin testing patients. The company has expanded its commercial team with three senior sales hires and will appoint a director of clinical partnerships later this month. The company said it remains on course to meet full-year market expectations. In a separate statement, Verici said Aubrey Powell has joined the board as a non-executive director, replacing Dr Erik Lium, who steps down after four years representing Mount Sinai. The shares rose 0.15p to 0.80p. Verici Dx PLC (AIM:VRCI) shares surged 23% following a highly encouraging update on its commercial execution. The company reported the onboarding of nine new U.S. transplant centers for its Tutivia test in Q3, bringing its total to 30 centers, which represent a significant 16% of the annual U.S. transplant market. This expansion in reach is underscored by strong adoption metrics, including a 19% increase in clinician orders over the period. Management has expressed confidence in an acceleration of sales volumes for the final quarter, a projection supported by the strategic expansion of its commercial team. The company's reaffirmation that it is on track to meet full-year market expectations signals that current operational performance is robust and aligned with its growth targets, underpinning the positive market reaction.

Key Decisions for Investors

• Given the demonstrated commercial traction, with 16% market penetration and a 19% increase in clinician orders, investors may view the positive momentum as supportive of a bullish thesis on the company's growth trajectory.
• Monitor Q4 sales volume data and the company's ability to meet its full-year guidance, as these will be critical validation points for the current valuation and future growth assumptions.
• While the operational update is positive, the 23% share price surge suggests the good news may be largely priced in for the near term; it is prudent to be mindful of this recent volatility and the potential for consolidation.